157 related articles for article (PubMed ID: 38150061)
1. Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
Bennebroek CA; Schouten CR; Montauban-van Swijndregt MC; Saeed P; Porro GL; Pott JWR; Dittrich ATM; Oostenbrink R; Schouten-van Meeteren AY; de Jong MC; de Graaf P
J Neurooncol; 2024 Jan; 166(1):79-87. PubMed ID: 38150061
[TBL] [Abstract][Full Text] [Related]
2. Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1.
Avery RA; Mansoor A; Idrees R; Trimboli-Heidler C; Ishikawa H; Packer RJ; Linguraru MG
Neurology; 2016 Dec; 87(23):2403-2407. PubMed ID: 27815398
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review.
Yamasaki F; Takano M; Yonezawa U; Taguchi A; Kolakshyapati M; Okumichi H; Kiuchi Y; Kurisu K
Childs Nerv Syst; 2020 Mar; 36(3):635-639. PubMed ID: 31701281
[TBL] [Abstract][Full Text] [Related]
4. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.
Sellmer L; Farschtschi S; Marangoni M; Heran MKS; Birch P; Wenzel R; Mautner VF; Friedman JM
Orphanet J Rare Dis; 2018 Apr; 13(1):62. PubMed ID: 29685181
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
6. Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.
Kilian A; Aigner A; Simon M; Salchow DJ; Potratz C; Thomale UW; Hernáiz Driever P; Tietze A
J Neurooncol; 2022 Feb; 156(3):589-597. PubMed ID: 34994964
[TBL] [Abstract][Full Text] [Related]
7. Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.
Chang L; El-Dairi MA; Frempong TA; Burner EL; Bhatti MT; Young TL; Leigh F
J AAPOS; 2010 Dec; 14(6):511-7. PubMed ID: 21168074
[TBL] [Abstract][Full Text] [Related]
8. Automatic Visual Acuity Loss Prediction in Children with Optic Pathway Gliomas using Magnetic Resonance Imaging.
Jiang Z; Parida A; Anwar SM; Tang Y; Roth HR; Fisher MJ; Packer RJ; Avery RA; Linguraru MG
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-5. PubMed ID: 38083430
[TBL] [Abstract][Full Text] [Related]
9. The Utility of Early Brain MRI for Patients with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Long-Term Follow-Up in a Tertiary Referral Hospital.
Rony C; Aharoni S; Halevy A
Neuropediatrics; 2022 Oct; 53(5):370-375. PubMed ID: 35381604
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Role of Conventional and Dynamic Contrast-Enhanced MRI in Optic Pathway Gliomas.
Jittapiromsak N; Hou P; Liu HL; Sun J; Slopis JM; Chi TL
J Neuroimaging; 2017 Nov; 27(6):594-601. PubMed ID: 28524459
[TBL] [Abstract][Full Text] [Related]
11. Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma.
Boonzaier NR; Hales PW; D'Arco F; Walters BC; Kaur R; Mankad K; Cooper J; Liasis A; Smith V; O'Hare P; Hargrave D; Clark CA
Neuroimage Clin; 2020; 28():102447. PubMed ID: 33038669
[TBL] [Abstract][Full Text] [Related]
12. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.
Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191
[TBL] [Abstract][Full Text] [Related]
14. Optic pathway glioma and endocrine disorders in patients with and without NF1.
Gil Margolis M; Yackobovitz-Gavan M; Toledano H; Tenenbaum A; Cohen R; Phillip M; Shalitin S
Pediatr Res; 2023 Jan; 93(1):233-241. PubMed ID: 35538247
[TBL] [Abstract][Full Text] [Related]
15. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.
Thiagalingam S; Flaherty M; Billson F; North K
Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338
[TBL] [Abstract][Full Text] [Related]
17. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
18. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK
J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
[TBL] [Abstract][Full Text] [Related]
19. The effect of chemotherapy on optic pathway gliomas and their sub-components: A volumetric MR analysis study.
Shofty B; Mauda-Havakuk M; Weizman L; Constantini S; Ben-Bashat D; Dvir R; Pratt LT; Joskowicz L; Kesler A; Yalon M; Ravid L; Ben-Sira L
Pediatr Blood Cancer; 2015 Aug; 62(8):1353-9. PubMed ID: 25858021
[TBL] [Abstract][Full Text] [Related]
20. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
